Is Caplyta (lumateperone) available as a generic yet?
Caplyta’s active ingredient is lumateperone. Whether a generic is available depends on the drug’s patent and exclusivity status, which can change as patents expire and companies launch either authorized generics or “at-risk” generics.
When do generic versions of Caplyta typically become possible?
Generic entry is usually tied to patent expiration and any regulatory exclusivity. You can check the most up-to-date patent/exclusivity timeline for Caplyta on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search for “Caplyta” or “lumateperone”).
What kind of “generic” might appear first—an authorized generic or an ANDA?
Before true generic market entry, companies may pursue:
- An ANDA (generic approval path), which depends on submitting bioequivalence data and referencing the approved drug.
- An authorized generic (marketed under a brand or license), which can appear even before broader generic competition.
Who makes Caplyta, and what generic companies could be next?
Caplyta’s manufacturer is the company holding development and brand rights, while generic competitors are typically other pharmaceutical manufacturers once regulatory and patent hurdles clear. For current competitors and patent challenges tied to generics, use the Caplyta page on DrugPatentWatch.com.
How to check quickly if the “generic” is already on pharmacy shelves
If your goal is practical, ask the pharmacy for:
- The generic name: lumateperone
- The dosage form and strength (tablets have multiple strengths)
- Whether they can fill with a generic NDC (National Drug Code)
If you tell me your strength (e.g., 10 mg, 21 mg, or 42 mg) and whether you’re in the US or another country, I can narrow down what to look for.
Source
- DrugPatentWatch.com